Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | galactokinase, putative | 0.0495 | 1 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.023 | 0.2298 | 0.5 |
Trichomonas vaginalis | galactokinase, putative | 0.023 | 0.2298 | 0.5 |
Leishmania major | galactokinase-like protein | 0.0495 | 1 | 1 |
Loa Loa (eye worm) | galactokinase | 0.023 | 0.2298 | 1 |
Treponema pallidum | galactokinase | 0.043 | 0.813 | 1 |
Mycobacterium leprae | Probable 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase IspE (CMK) (4-(cytidine-5'-diphospho)-2-C-methyl-D-erythritol kinase) | 0.0151 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | 0.0151 | 0 | 0.5 |
Entamoeba histolytica | galactokinase, putative | 0.0495 | 1 | 0.5 |
Echinococcus multilocularis | N acetylgalactosamine kinase | 0.023 | 0.2298 | 0.2298 |
Giardia lamblia | Mevalonate kinase | 0.0151 | 0 | 0.5 |
Trypanosoma cruzi | galactokinase, putative | 0.043 | 0.813 | 0.813 |
Trypanosoma cruzi | galactokinase-like protein, putative | 0.043 | 0.813 | 0.813 |
Toxoplasma gondii | GHMP kinase, N-terminal domain-containing protein | 0.023 | 0.2298 | 1 |
Echinococcus multilocularis | galactokinase | 0.0495 | 1 | 1 |
Brugia malayi | galactokinase family protein | 0.023 | 0.2298 | 1 |
Trypanosoma brucei | galactokinase-like protein, putative | 0.0328 | 0.5161 | 1 |
Mycobacterium ulcerans | galactokinase | 0.0495 | 1 | 1 |
Schistosoma mansoni | galactokinase | 0.023 | 0.2298 | 1 |
Echinococcus granulosus | N acetylgalactosamine kinase | 0.023 | 0.2298 | 0.2298 |
Mycobacterium tuberculosis | Probable galactokinase GalK (galactose kinase) | 0.0495 | 1 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.023 | 0.2298 | 0.5 |
Trichomonas vaginalis | galactokinase, putative | 0.023 | 0.2298 | 0.5 |
Trypanosoma cruzi | galactokinase, putative | 0.0495 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.